北京生物医药产业创新体系及其创新能力评价研究  

Research on Beijing Biopharmaceutical Industrial Innovation System and Innovation Ability Evaluation

作　　者：冯昊[1,2] 雷霆[1] 潘悦[2] 吴曙霞[1] 奚大龙 

机构地区：[1]军事医学科学院,北京100850 [2]北京生物技术和新医药产业促进中心,北京100193 [3]北京嘉乐世纪科技有限公司,北京100022

出　　处：《中国医药工业杂志》2017年第7期1075-1082,共8页Chinese Journal of Pharmaceuticals

摘　　要：北京生物医药产业己进入创新驱动发展的关键时期,产业创新体系是其重要支撑和保障。基于产业创新体系的视角,从创新要素、创新环境、创新过程和创新效益四个维度研究北京生物医药产业创新体系,构建其创新能力评价指标体系,定量分析其2009~2015年创新能力发展情况,并结合评价结果进行SWOT定性分析。结果显示,北京生物医药产业2009~2012年创新能力稳步提升,2013~2014年出现下降,2015年出现上升拐点。结论:本文研究启示我国生物医药需进一步加快从传统的"生产"思维向"创新"思维转变,从"生产创造价值"向"知识创造价值"转变,才能真正实现以知识为价值导向的利益分配,面向全球和全国分享创新所带来的经济价值。Beijing biopharnlaceutical industry is now at a critical stage of innovation-driven development, with the industrial innovation system being important support and guarantee for its development. Based on the perspective of industrial innovation system, this paper studies the innovation system of Beijing biopharmaceutical industry from the four dimensions of innovation factor, innovation environment, innovation process and innovation benefits, constructs its innovation ability evaluation system, and quantitatively analyzes its innovation capacity development status between 2009 and 2015. The results show that the innovation ability of Beijing biopharmaceutical industry improved steadily between 2009 and 2012, declined in 2013 and 2014, and bottomed out in 2015. A SWOT qualitative analysis conducted in combination with evaluation results shows that Beijing biopharmaceutical industry has advantages in the innovation vitality and innovation resources of enterprises, while its weaknesses lie in the areas of achievements transformation and government administration. Going forward, Beijing biophannaceutical industry will face both opportunities and threats in its development.

关 键 词：生物医药产业 产业创新体系 创新评价 SWOT分析 

分 类 号：R95[医药卫生—药学]